特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
950567

片頭痛薬の世界市場:2019年~2026年

Global Migraine Drugs Market - 2019-2026

出版日: | 発行: DataM Intelligence | ページ情報: 英文 | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
片頭痛薬の世界市場:2019年~2026年
出版日: 2020年07月18日
発行: DataM Intelligence
ページ情報: 英文
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

片頭痛はおそらく神経学における障害の最も一般的な原因です。近年、片頭痛の症例が大幅に増加しています。たとえば、2015年の国立バイオテクノロジー情報センターによると、片頭痛は、人生のある時点で20%以上の人々に影響を与えているとされています。疫学調査によると、西欧の人口のほぼ4.5%が少なくとも月に15日間頭痛を抱えています。研究によれば、片頭痛はまた、 米国で3,100万人以上の人々に影響を及ぼし、 米国で 3番目に一般的な疾患であり、おそらく2番目の主要な障害の原因でさえあります。したがって、片頭痛治療の急増は、市場成長の主要な要因であると予想されます。さらに、体に有害な製品の使用の増加と慢性疾患の有病率の増加は、片頭痛薬の需要の高まりの主な要因となっています。

片頭痛薬に関連する副作用は、市場成長を抑制する可能性があります。ただし、可処分所得の増加と片頭痛患者の増加により、新興市場の需要が高まっているため、市場参加企業に幅広い成長機会が見込まれています。

当レポートでは、世界の片頭痛薬市場について調査分析し、業界分析、セグメント別の市場分析、競合情勢、主要企業などについて、体系的な情報を提供しています。

目次

第1章 市場調査方法と範囲

  • 調査方法
  • 調査範囲の 調査目的と範囲

第2章 市場定義と概要

第3章 エグゼクティブサマリー

  • タイプ別市場内訳
  • 投薬経路別市場内訳
  • 流通チャネル別市場内訳
  • 地域市場内訳

第4章 市場のダイナミクス

  • 市場に影響を与える要因
    • 成長要因
    • 抑制要因
    • 影響分析
  • 市場機会
  • 動向

第5章 業界分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 規制分析
  • 価格分析

第6章 世界の片頭痛薬市場-タイプ別

  • イントロダクション
    • タイプ別市場規模分析、および前年比成長分析(%)
    • タイプ別市場魅力度指数
  • 進行予防薬
    • イントロダクション
    • 市場規模分析(100万米ドル)2017年~2026年、および前年比成長分析(%)2018年~2026年
  • 予防薬

第7章 世界の片頭痛薬市場-投薬経路別

  • イントロダクション
    • 投薬経路別の市場規模分析、および前年比成長分析(%)
    • 投薬経路別市場魅力指数
  • 経口
  • 注射剤
  • その他

第8章 世界の片頭痛薬市場-流通チャネル別

  • イントロダクション
    • 流通チャネル別の市場規模分析、および前年比成長分析(%)
    • 流通チャネル別市場魅力度指数
  • 病院内薬局
    • イントロダクション
    • 市場規模分析(100万米ドル)2016年~2025年、および前年比成長分析(%)2018年~2026年
  • 小売薬局
  • オンライン薬局

第9章 地域別の片頭痛治療薬の世界の市場

  • イントロダクション
    • 市場規模分析、および前年比成長率分析(%)、地域別
    • 地域別市場魅力度指数
  • 北米
    • イントロダクション
    • 主な地域固有のダイナミクス
    • タイプ別市場規模分析、および前年比成長分析(%)
    • 投薬経路別市場規模分析、および前年比成長分析(%)
    • 流通チャネル別の市場規模分析、および前年比成長分析(%)
    • 国別の市場規模分析、および前年比成長分析(%)
  • 欧州
    • イントロダクション
    • 主な地域固有のダイナミクス
    • タイプ別市場規模分析、および前年比成長分析(%)
    • 投薬経路別市場規模分析、および前年比成長分析(%)
    • 流通チャネル別の市場規模分析、および前年比成長分析(%)
    • 国別の市場規模分析、および前年比成長分析(%)
  • 南米
    • イントロダクション
    • 主な地域固有のダイナミクス
    • タイプ別市場規模分析、および前年比成長分析(%)
    • 投薬経路別市場規模分析、および前年比成長分析(%)
    • 流通チャネル別の市場規模分析、および前年比成長分析(%)
    • 国別の市場規模分析、および前年比成長分析(%)
  • アジア太平洋
    • イントロダクション
    • 主な地域固有のダイナミクス
    • タイプ別市場規模分析、および前年比成長分析(%)
    • 投薬経路別市場規模分析、および前年比成長分析(%)
    • 流通チャネル別の市場規模分析、および前年比成長分析(%)
    • 国別の市場規模分析、および前年比成長分析(%)
  • 中東とアフリカ
    • イントロダクション
    • 主な地域固有のダイナミクス
    • タイプ別市場規模分析、および前年比成長分析(%)
    • 投薬経路別市場規模分析、および前年比成長分析(%)
    • 流通チャネル別の市場規模分析、および前年比成長分析(%)

第10章 競合情勢

  • 競合シナリオ
  • 市場ポジショニング/シェア分析
  • 合併と買収の分析

第11章 企業プロファイル

  • Abbott Laboratories
    • 企業概要
    • ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • AbbVie Inc
  • Allergan Plc..
  • AstraZeneca PLC.
  • Eisai Co., Ltd.
  • Endo International Plc.
  • GlaxoSmithKline Plc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Johnson & Johnson
  • その他

第12章 世界の片頭痛薬市場- 重要考察

第13章 世界の片頭痛薬市場:DataM

  • 付録
  • 当社およびサービスについて
  • お問い合わせ
目次

Market Overview

Migraine is a condition of the neurology which can cause multiple symptoms. It is marked often by severe and debilitating headaches. Symptoms can include nausea, vomiting, difficulty speaking, numbness or tingling, and others. Migraines occur inside families and influence all ages. Diagnosis of migraine headaches is assessed from clinical history and reported symptoms. Migraines may arise in infancy or may not appear until early adulthood. Females are more prone to experience migraines than men. Genetic background is one of the most common sign factors for migraines. Symptoms of migraines will start one to two days before the headache itself. This is classified as a stage of the prodrome. Migraine pain more often impacts the area of the forehead. It's normally on one side of the head, but on both sides, it may occur. The Migraine Drugs market valued USDXX million in 2018 and it is expected to grow at a CAGR of XX% to reach USD XX million by 2026.

Market Dynamics:

Migraine is perhaps the most common cause of disability in neurology. There has been a substantial increase in migraine cases in recent years. For instance, in 2015, As per the National Center for Biotechnology Information, migraine impacts more than 20 percent of people at some point in their lives in 2015; epidemiological studies have shown that almost 4.5 percent of Western Europe's population has a headache on at least 15 days a month. As per the study, migraine also affects upwards of 31 million people in the United States and is the third most common disease and perhaps even the second leading cause of disability worldwide. Thus, a surge in migraine medications is expected to be a key factor in market growth. In addition, the growing use of unhealthy products and the increasing prevalence of chronic disease are the main factors responsible for the rise of the demand for migraine drugs.

Side effects associated with migraine drugs may act as restrain for market growth. However, there is growing demand emerging market, due to rising disposal income and increasing numbers of migraine patients are expected to present a wide range of growth opportunities for market players.

Segment Analysis

Global migraine drugs are segmented into treatment type, route of administration, and distribution channel. Based on the treatment type, the market is segmented into prophylactic and abortive. On the basis of route of administration, the market is segmented into injectable, oral, and others. Based in distribution channel, the global migraine drugs market is diversified as hospital pharmacies, retail pharmacies, and others.

Currently, there are three novel drugs in late-stage pipeline that are set to change the treatment landscape. These drugs follow disease-modifying approaches and are associated with superior clinical efficacy and a favorable safety profile compared to currently marketed drugs.

Allergan's ubrogepant and Eli Lilly's Lasmiditan are expected to be first-in-class migraine drugs with novel mechanism of actions for patients unresponsive to triptans or those who are at risk of cardiovascular disorders.Several triptans under late-stage development consist of reformulation of generic triptans, with an aim to improve the efficacy of existing formulations. Zosano Pharma's M207 is being investigated in Phase III ADAM (NCT03282227) trial. The drug is a novel formulation of zolmitriptan delivered via Zosano's proprietary Adhesive Dermally-Applied Microarray (ADAM) technology.

Geographical Presentation

By region, the Migraine Drugs market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the Migraine Drugs market due to the high usage of the Migraine Drugs. Additionally, Migraine is the third most prevalent and the sixth most disabling illness in the world, affecting more than 37 million in the U.S. and over one billion people worldwide. United States dominated the market with more than 65% share in 2017 and is projected to maintain its position until 2025. Launch of CGRP based therapies, high prevalence, increasing adoption of novel therapeutics, and a large target population in the U.S. is some of the factors contributing to the dominance of the country

Competitive Analysis

Key players operating in the market are Allergen, Eisai, Ltd., AstraZeneca plc, Abbott Laboratories, and others. Leading multinational players dominate the market and hold substantial market share, thereby, presenting tough competition to new entrants. Key players focus on various strategic initiatives such as merger & acquisition, geographical expansion, new product launch and increasing R&D expenditure to stay competitive in the market. For instance, in 2019 Allergen Company announced that a New Drug Application for UBRELVY for the acute treatment of migraines with or without aura in adults. This drug was approved by the Food and Drug Administration (United States). This acquisition will affect the growth of the market in the future.

Until 2017, Allergan's Botox, a neurotoxin was in a strong competitive position in the preventive migraine market. As the only drug approved for prevention, Botox commanded premium pricing with more than 60.0% market share in 2017. However, Botox is expected to face competition from launch of Amgen/Novartis' Aimovig and other highly efficacious CGRP-based therapies, which target both chronic and episodic migraine, as opposed to Botox, which is only approved for the chronic variant of the condition.

Why Purchase the Report?

  • Visualize the composition of the Migraine Drugs market products in terms of data type, business function, component, deployment model, organization size, and industrial vertical highlighting the critical commercial assets and players.
  • Identify commercial opportunities in the Migraine Drugs market by analyzing trends and co-development deals.
  • Excel datasheet with thousands of data points of global Migraine Drugs market-level4/5segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • *The global Migraine Drugs market report will provide access to approximately 63 Market data tables, 51 figures, and 178 pages

Target Audience

  • Drug Manufacturers
  • Drug Suppliers, Distributors
  • Government Regulatory Bodies
  • Market Research Organization
  • Others

Table of Contents

1. Global Migraine Drugs Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Migraine Drugs Market-Market Definition and Overview

3. Global Migraine Drugs Market-Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Route of Admistration
  • 3.3. Market Snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Global Migraine Drugs Market-Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Impact Analysis
  • 4.2. Opportunity
  • 4.3. Trends

5. Global Migraine Drugs Market-Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis

6. Global Migraine Drugs Market - By Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis(%), By Type
    • 6.1.2. Market Attractiveness Index, By Type
  • 6.2. Abortive Medicine *
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis,USDMn,2017-2026 and Y-o-Y Growth Analysis(%),2018-2026
  • 6.3. Preventive Medicine

7. Global Migraine Drugs Market - By Route of Admistration

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis(%), By Route of Admistration
    • 7.1.2. Market Attractiveness Index, By Route of Admistration
  • 7.2. Oral*
      • 7.2.1.1. Introduction
      • 7.2.1.2. Market SizeAnalysis,US$Mn,2016-2025andY-o-YGrowthAnalysis(%),2018-2026
  • 7.3. Injectable
  • 7.4. Others

8. Global Migraine Drugs Market - By Distribution Channel

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis(%), By Distribution Channel
    • 8.1.2. Market Attractiveness Index, By Distribution Channel
  • 8.2. Hospital-Based Pharmacies*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
  • 8.3. Retail Pharmacies
  • 8.4. Online Pharmacies

9. Global Migraine Drugs Market-By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, andY-o-Y Growth Analysis(%),By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis(%), By Type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis(%),By Route of Admistration
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis(%),By Distribution Channel
    • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis(%),By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis(%), By Type
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis(%),By Route of Admistration
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis(%),By Distribution Channel
    • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis(%),By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis(%), By Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis(%),By Route of Admistration
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis(%),By Distribution Channel
    • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis(%),By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis(%), By Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis(%),By Route of Admistration
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis(%),By Distribution Channel
    • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis(%),By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. Australia
      • 9.5.6.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis(%), By Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis(%),By Route of Admistration
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis(%),By Distribution Channel

10. Global Migraine Drugs Market Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Global Migraine Drugs Market Company Profiles

  • 11.1. Abbott Laboratories *
    • 11.1.1. Company Overview
    • 11.1.2. Form Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. AbbVie Inc
  • 11.3. Allergan Plc..
  • 11.4. AstraZeneca PLC.
  • 11.5. Eisai Co., Ltd.
  • 11.6. Endo International Plc.
  • 11.7. GlaxoSmithKline Plc.
  • 11.8. Merck & Co., Inc.
  • 11.9. Pfizer Inc.
  • 11.10. Johnson & Johnson
  • List is not exhaustive

12. Global Migraine Drugs Market-Premium Insights

13. Global Migraine Drugs Market-DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.